Scrip    Clinica    Scrip Regulatory Affairs    Scrip Clinical Research    AnimalPharm   
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Pricing & Reimbursement
|
Regulation
|
Healthcare Policy
|
Pharmacovigilance
|
Intellectual Property
|
Policy & Regulation
EVENTS
09 February 2012
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK Promote your vacancy here
Genentech goes beyond Infinity with FDA OK to sell Hedgehog inhibitor for advanced BCC
31 January 2012
Well ahead of its PDUFA deadline of 8 March, the US FDA on January 30 gave Roche's Genentech arm the green light to sell vismodegib as the first nonsurgical treatment for advanced basal cell carcinoma (BCC). The company said that the once-a-day capsule will be on the US market under the trade name Erivedge before mid-February. Last month Roche filed for approval of the drug with the EMA ( scripintelligence.com, 23 December 2011 ). It is intended for the small group of BCC patients for whom the ...
 
Stockwatch: A slimmer AstraZeneca starts to look tasty
03 February 2012
The headline number when AstraZeneca announced its full-year 2011 results on February 2 was not the sales or earnings numbers, but the 7,300 further job losses from R&D, sales and marketing, and manufacturing ( scripintelligence.com, 3 February 2012 ). The AstraZeneca share price finished the day ...
Janssen's Zytiga fails to impress NICE
02 February 2012
Janssen Cilag has failed to convince NICE, the health technology appraisal institute for England and Wales, that its oral prostate cancer drug Zytiga (abiraterone), provides enough benefit to justify thecost. Today's draft recommendations come despite the offer of a patient access scheme and NICE's ...
 
What do promising prostate cancer drug results mean for Dendreon?
02 February 2012
Three months ago, Medivation announced encouraging top-line results for the prostate cancer androgen receptor signalling inhibitor it is developing in conjunction with Astellas Pharma ( scripintelligence.com, 3 November 2011 ). On February 1 it released more details of the findings of its AFFIRM ...
EMA lays out drug safety priorities for 2012
03 February 2012
Priorities for the European Medicines Agency in the drug safety area this year include a new urgent referral procedure, guidance on post-authorisation efficacy studies, and more effective ways of detecting and acting on significant safety signals. The EMA will also be preparing for the inaugural ...
 
EMA lays out drug safety priorities for 2012
03 February 2012
Priorities for the European Medicines Agency in the drug safety area this year include a new urgent referral procedure, guidance on post-authorisation efficacy studies, and more effective ways of detecting and acting on significant safety signals. The EMA will also be preparing for the inaugural ...
Janssen's Zytiga fails to impress NICE
02 February 2012
Janssen Cilag has failed to convince NICE, the health technology appraisal institute for England and Wales, that its oral prostate cancer drug Zytiga (abiraterone), provides enough benefit to justify the cost. Today's draft recommendations come despite the offer of a patient access scheme and ...
 
What do promising prostate cancer drug results mean for Dendreon?
02 February 2012
Three months ago, Medivation announced encouraging top-line results for the prostate cancer androgen receptor signalling inhibitor it is developing in conjunction with Astellas Pharma ( scripintelligence.com, 3 November 2011 ). On February 1 it released more details of the findings of its AFFIRM ...
EMA lays out drug safety priorities for 2012
03 February 2012
Priorities for the European Medicines Agency in the drug safety area this year include a new urgent referral procedure, guidance on post-authorisation efficacy studies, and more effective ways of detecting and acting on significant safety signals. The EMA will also be preparing for the inaugural ...
 
US Capitol Capsule: Obama seeks to secure global supply chain; reveals new plan
30 January 2012
Realizing that a catastrophe in one nation, as evidenced by the March 2011 earthquake-tsunami-nuclear crisis in Japan, can result in a major threat to drugs and other goods in the global supply chain – which is growing increasingly more complex – the Obama administration last week laid out a new ...
European industry bodies voice concern over CoE's anti-counterfeiting system
30 January 2012
Moves towards implementing a Europe-wide system for verifying the authenticity of medicines are gathering pace as representatives of the pharmaceutical industry and distributors prepare to sign an agreement on what they say will be a "practical and cost-effective solution" to implementing the ...
 

2012 Scrip 100: Survival of the fittest
29 December 2011

It’s finally here. For a while, a dark cloud has been looming ominously over the industry and, on ...

2012 Scrip 100: Successful trial outcomes – peering into the crystal ball
29 December 2011

With rising trial costs and shrinking budgets, pharma companies are working more diligently than ...

2012 Scrip 100: Work-Life balance tops salary for pharma employees
28 December 2011

Four years ago, Scrip 100 surveyed a broad and representive sample of those working in the ...

Sanofi: Aubagio's tolerability profile is key differentiator in light of lacklustre efficacy
22 December 2011
The recent Phase III results from the TENERE study of Sanofi 's Aubagio (teriflunomide) comparing ...

Dx by dt: diagnostic intent over time
03 February 2012
Mike Ward
If Roche acquires Illumina, as it seems fairly intent on doing despite repeated messages of ...

© 2012 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
Scrip Regulatory Affairs
Scrip Clinical Research
Animal Pharm